Vyera Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
44 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
2020-001996-33: A Phase 2b/3 Study to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (COVID-19)

Not yet recruiting
3
290
Europe
Leronlimab(PRO 140), Injection, Leronlimab Injection 175mg/ml (PRO-140)
CytoDyn, Inc., CytoDyn, Inc.
Coronavirus Disease 2019 (COVID-19), Coronavirus Disease, Diseases [C] - Virus Diseases [C02]
 
 
NCT02859961: Study of PRO 140 SC As Single Agent Maintenance Therapy in Virally Suppressed Subjects with CCR5-tropic HIV-1 Infection

Completed
2/3
556
US
PRO 140 (350 mg), Leronlimab, PRO 140 (525 mg), PRO 140 (700 mg)
CytoDyn, Inc.
HIV
09/20
12/20
NCT02990858: An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 Study

Active, not recruiting
2/3
44
NA
PRO 140 SC injections
CytoDyn, Inc.
Hiv, Human Immunodeficiency Virus
06/22
08/22
NCT03902522: PRO 140 in Treatment-Experienced HIV-1 Subjects

Active, not recruiting
2/3
25
US
PRO 140, Leronlimab
CytoDyn, Inc.
HIV-1-infection
07/22
08/22
PRO 140_CD03 Extension, NCT05271370: An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study

Active, not recruiting
2/3
56
US
PRO 140 350, PRO 140 525, PRO 140 700
CytoDyn, Inc.
HIV-1-infection
12/22
04/23
NCT04347239 / 2020-001996-33: Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)

Active, not recruiting
2b
394
US
Placebos, Leronlimab (700mg)
CytoDyn, Inc., CytoDyn, Inc.
Coronavirus Disease 2019
10/21
06/22
NCT04504942: Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
2
30
US
Leronlimab
CytoDyn, Inc., Amarex Clinical Research
Solid Tumor, Adult
11/21
07/22
NCT04521114: Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis

Completed
2
87
US
Placebo, leronlimab 700 mg, PRO 140, leronlimab 350 mg
CytoDyn, Inc., Amarex Clinical Research
Nonalcoholic Steatohepatitis (NASH)
12/21
12/21
NCT02355184: An Extension of Protocol PRO 140_CD01 TS Study

Active, not recruiting
2
28
US
PRO 140 350mg weekly SQ injection., PRO 140
CytoDyn, Inc.
HIV, Human Immunodeficiency Virus
06/22
08/22
NCT05730673: Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer

Withdrawn
2
NA
700mg leronlimab weekly dose, 80mg Regorafenib at week 1, 120mg Regorafenib at week2, 160 mg Regorafenib at week 3
CytoDyn, Inc., Amarex Clinical Research
CCR5, Microsatellite Stable, Metastatic, Colorectal Cancer
05/23
08/23
NCT06699836: A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC

Recruiting
2
60
US
350 mg leronlimab, PRO 140, 700 mg leronlimab
CytoDyn, Inc., Syneos Health
Metastatic Colorectal Cancer (mCRC)
06/28
08/28
NCT03838367: Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC

Active, not recruiting
1/2
48
US
350 mg leronlimab, PRO 140, 525 mg leronlimab, 700 mg leronlimab, AUC 5 Carboplatin, Maximum Tolerated Dose (MTD) of leronlimab
CytoDyn, Inc., Amarex Clinical Research
Triple Negative Breast Neoplasms
07/22
09/22
CD02_EA, NCT02759042: An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study

No Longer Available
N/A
US
PRO 140, PRO140, CCR5 antagonist, Humanized monoclonal antibody to CCR5
CytoDyn, Inc., Amarex Clinical Research
HIV
 
 
NCT04313075: A Compassionate Use Study of Leronlimab in Breast Cancer

No Longer Available
N/A
NA
Leronlimab, (PRO 140)
CytoDyn, Inc.
Metastatic Triple-Negative Breast Carcinoma
 
 
Syntocinon Nasal Spray (oxytocin intranasal) / Vyera Pharma
2012-003072-39: Oxytocin in PTSD: Effectiveness in addition to psychotherapy Oxytocine bij PTSS: Effectiviteit als toevoeging aan psychotherapie

Ongoing
4
24
Europe
Nasal drops, solution, Syntocinon, nasal spray 40 IU/ml
Academic Medical Center, University of Amsterdam, Academic Medical Center, University of Amsterdam
Posttraumatic stress disorder Posttraumatische stress stoornis, posttraumatic stress disorder posttraumatische stress stoornis, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2013-000453-44: Oxytocin, defensiveness, and grandparenting

Ongoing
4
100
Europe
Syntocinon, RVG03716, Nasal spray, Syntocinon
There are no medical conditions or diseases under investigation, There are no medical conditions or diseases under investigation, Not possible to specify
 
 
2013-000454-22: (Grand)parenting, oxytocin, and the oxytocin receptor gene

Ongoing
4
100
Europe
Syntocinon, RVG03716, Nasal spray, Syntocinon
There are no medical conditions or diseases under investigation, not applicable, Not possible to specify
 
 
2015-003336-12: Father Trials: Hormonal Experiments on Prenatal and Postnatal Parenting

Ongoing
4
120
Europe
Syntocinon, Vasostrict, RVG03716, 42023-164-25, Nasal spray, Injection, Syntocinon, Vasostrict
Universiteit Leiden, European Research Council
There are no medical conditions or diseases under investigation, There are no medical conditions or diseases under investigation, Not possible to specify
 
 
2016-000367-16: The oxytocin effect in adolescence

Ongoing
4
256
Europe
oxytocin, oxytocin, Nasal spray, Syntocinon Nasal Spray
Radboud University Nijmegen, Radboud University Nijmegen
We examine the effect of oxytocin administration on empathy and emotion recognition in healthy adolescents and adolescents with antisocial behavior and history of severe psychological trauma, adolescents with antisocial behavior and history of trauma, Psychiatry and Psychology [F] - Behaviours [F01]
 
 
2017-000298-35: Oxytocin, friendship and dealing with emotions

Ongoing
4
180
Europe
Syntocinon, RVG 03716, Nasal spray, Syntocinon nasal spray
Tilburg University, Tilburg University, Center of Research on Psychological and Somatic disorders
There are no medical conditions or disease under investigation. Er worden geen ziekten onderzocht, not applicable niet van toepassing, Psychiatry and Psychology [F] - Psychological processes [F02]
 
 
2018-004081-34: Oxytocin and the relationship between doctor and patient. Oxytocine en de relatie tussen arts en patient

Ongoing
4
76
Europe
Oxytocin, Oxytocin, Nasal spray, Syntocinon nasal spray
Healthy individuals, Healthy individuals, Psychiatry and Psychology [F] - Psychological processes [F02]
 
 
2022-003670-22: Clinical trial to evaluate the efficacy of the combination of oxytocin plus self-compassion training in patients with Borderline Personality Disorder Estudio para evaluar la eficacia de la combinación de oxitocina más entrenamiento en autocompasión en pacientes con Trastorno Límite de Personalidad

Not yet recruiting
4
80
Europe
Nasal spray, solution, Syntocinon
Institut de Recerca Hospital de la Santa Creu i Sant Pau - IIB Sant Pau, Instituto de Salud Carlos III
Borderline personality disorder Trastorno Límite de la Personalidad, Borderline personality disorder Trastorno Límite de la Personalidad, Psychiatry and Psychology [F] - Behaviours [F01]
 
 
2013-004437-33: Effets de l'administration intranasale répétée d'ocytocine chez des patients adultes présentant un syndrome de Prader-Willi

Ongoing
3
39
Europe
Nasal spray, Syntocinon
Centre Hospitalier de Toulouse, Centre Hospitalier de Toulouse
Prader-Willi syndrom Syndrome de Prader-Willi, Prader-Willi syndrom syndrome de Prader-Willi, Diseases [C] - Hormonal diseases [C19]
 
 
2010-024202-34: group-therapy, autism and oxytocin - an investigation with the question "Does oxytocin (OT) enhance therapy effects in autism?“ Gruppentherapie, Autismus und Oxytocin - Eine Untersuchung, mit der Fragestellung: "Erhöht Oxytocin den Therapieeffekt bei Autisten?"

Ongoing
3
210
Europe
SyntocinonⓇSpray, 11.266, Nasal spray, SyntocinonⓇSpray
Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters am Zentralinstitut für Seelische Gesundheit, Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters am Zentralinstitut für Seelische Gesundheit
high-functioning autismus spectrum disorders: autistic disorder (F84.0), Asperger syndrome (F84.5), atypical autism (F84.1) Hochfunktionale Autismus-Spektrum-Störung: Frühkindlicher Autismus (F84.0), Asperger-Syndrom (F84.5), Atypischer Autismus (F84.1), autism Autismus, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2018-000769-35: The use of Oxytocin for Autism Spectrum Disorders: Investigating the effect on behavior and at the level of the brain.

Ongoing
3
60
Europe
Syntocinon (oxytocin), RVG 03716, Nasal spray, Syntocinon (oxytocin), nasal spray 40 IE/ml
University Hospital, KU Leuven, Research Council KU Leuven, Society In Science - ETH Zurich
Autism Spectrum Disorders, Autism Spectrum Disorders, Psychiatry and Psychology [F] - Psychological processes [F02]
 
 
2016-003273-18: Oxytocin intranasal administrations in children with Prader-Willi syndrome aged from 3 to 12 years.

Not yet recruiting
3
40
Europe
Nasal spray, Syntocinon
University Hospital of Toulouse, University Hospital of Toulouse
Prader-Willi Syndrom, Prader-Willi Syndrom, Diseases [C] - Hormonal diseases [C19]
 
 
2011-006302-28: Dopamine modulation of oxytocin prosocial effects Modulazione dopaminergica dell’effetto prosociale dell’ossitocina

Ongoing
2
50
Europe
Nasal spray, Syntocinon nasal Spray
UNIVERSITA' DEGLI STUDI DI PARMA, Defiante farmaceutica
HEALTHY VOLUNTEERS. FOR PATIENTS WITH AUTISM OR SCHIZOPHRENIA VOLONTARI SANI PER INDICAZIONE DESTINATA A PAZIENTI AUTISTICI O SCHIZOFRENICI, HEALTHY VOLUNTEERS. FOR PATIENTS WITH AUTISM OR SCHIZOPHRENIA VOLONTARI SANI PER INDICAZIONE DESTINATA A PAZIENTI AUTISTICI O SCHIZOFRENICI, Psychiatry and Psychology [F] - Behaviours [F01]
 
 
2012-005325-67: Evaluation of tolerance, suckling and food intake after repeated nasals administrations of Oxytocin in PWS infants Etude de tolérance d’administrations intranasales répétées d’ocytocine selon 3 schémas d’administration chez des bébés présentant un syndrome de Prader-Willi

Ongoing
2
18
Europe
Nasal spray, Syntocinon
Centre Hospitalier de Toulouse, Centre Hospitalier de Toulouse
Prader Willi Syndrom Syndrome de Prader-Willi, Prader Willi Syndrom Syndrome de Prader-Willi, Diseases [C] - Hormonal diseases [C19]
 
 
2014-005452-26: Effect of intranasal oxytocin on sosial cogitive tasks in autism spectrum disorder

Not yet recruiting
2
18
Europe
Oxytocin, Nasal spray, solution, Syntocinon
OptiNose AS, OptiNose AS
Autism spectrum disorder, Autism, Psychiatry and Psychology [F] - Psychological processes [F02]
 
 
2013-003067-59: Oxytocin Trial Protocollo Ossitocina

Ongoing
2
30
Europe
Syntocinon, N.A., Nasal spray, solution, Syntocinon
AZIENDA OSPEDALIERA G. BROTZU, Fondazione Banco di Sardegna
Autism Spectrum Disorder Disturbo dello Spettro Autistico, Is a condition charaterized by abnormalities in the domains of communication and socialization and by a restricted and repetitive pattern of interests and activities. E' una condizione clinica caratterizzata da anomalie nei settori della comunicazione e della socializzazione e da attivit¿ ridotte e ripetitive., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2014-004762-23: NO Etude de l’effet de l’ocytocine en spray nasal sur les activations cérébrales liées à l’attachement en population générale (OTACLA)

Not yet recruiting
2
80
Europe
syntocinon, Nasal spray, Syntocinon
CHRU Besançon, CHRU Besançon
sujets à l'attachement insécure sujets à l'attachement insécure, sujets à l'attachement insécure sujets à l'attachement insécure, Psychiatry and Psychology [F] - Psychological processes [F02]
 
 
2019-001910-40: Emotion recognition training combined with oxytocin in residential youth

Ongoing
2
60
Europe
oxytocin, RVG03716, Nasal spray, Syntocinon Nasal Spray
Radboud University, Radboud University
We examine whether oxytocin administration can improve the effectiveness of emotion recognition training compared to placebo in residential youth with antisocial behavior, Adolescents with antisocial behavior exhibiting aggression and delinquency, Psychiatry and Psychology [F] - Behaviours [F01]
 
 
2019-002280-10: Oxytocin nasal spray in the treatment of benzodiazepine withdrawal

Not yet recruiting
2
50
Europe
Syntocinon, Nasal spray, suspension, Syntocinon
St. Olav's University Hospital, St. Olavs University Hospital, Norwegiand University of Science and Technology, Lade Addiction Treatment Center
Benzodiazepine withdrawal and craving, Benzodiazepine withdrawal and craving, Not possible to specify
 
 
2022-000156-11: Oxytocin and the development of attachment: Looking beyond the expected? Oxytocine en de ontwikkeling van gehechtheid: een blik voorbij de verwachting?

Ongoing
2
200
Europe
Syntocinon (oxytocin), Nasal spray, Syntocinon (oxytocin), nasal spray 40 IE/ml
KU Leuven, FWO
General healthy population children (ages 8 - 13 years old). Gezonde kinderen uit de algemene populatie (tussen 8 en 13 jaar oud)., General population children (ages 8 - 13 years old). Gezonde kinderen uit de algemene populatie (tussen 8 en 13 jaar oud)., Psychiatry and Psychology [F] - Psychological processes [F02]
 
 
NCT06757517: Effects of Intranasal Oxytocin in the Treatment of Benzodiazepine Withdrawal: A Pilot RCT

Recruiting
2
60
Europe
Oxytocin nasal spray, Syntocinon, Saline (NaCl 0,9 %) (placebo)
St. Olavs Hospital, Norwegian University of Science and Technology, Lade Behandlingssenter, Blå Kors
Benzodiazepine Dependence
12/25
12/25
2022-000254-28: Interest of oxytocin as an adjuvant treatment of psycho-educational measures in challenging behaviors in children with autism spectrum disorders and moderate to severe intellectual disability: feasibility and safety study ntérêt de l’ocytocine comme traitement adjuvant des mesures psycho-éducatives dans les comportements-défis chez les enfants avec troubles du spectre de l’autisme et handicap intellectuel moyen à profond : l’étude de faisabilité et de sécurité

Not yet recruiting
2
30
Europe
Syntocinon (Oxytocin), Nasal spray, solution, Syntocinon
University Hospital of Toulouse, French Ministry of Health
autism autisme, autism autisme, Psychiatry and Psychology [F] - Behaviours [F01]
 
 
2022-000603-12: Oxytocin and postpartum depression

Not yet recruiting
2
35
Europe
oxytocin, RVG03716, Nasal spray, Syntocinon Nasal Spray
Radboud University, Radboud University
We examine the effects of oxytocin on mother-infant interaction among mothers with a postpartum depression, postpartum depression, Psychiatry and Psychology [F] - Behaviours [F01]
 
 
IN-OXT, NCT02505984: Preventing Postpartum Depression With Intranasal Oxytocin

Completed
2
56
US
Oxytocin, Syntocinon, Placebo, Salt solution
Massachusetts General Hospital, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Depression, Postpartum, Anxiety
05/23
05/23
2021-006531-26: A trial of intranasal oxytocin in youth with autism spectrum disorders evaluating social and repetitive behaviors

Not yet recruiting
2
128
Europe
Nasal spray, Syntocinon
Oslo University Hospital, Kavli Trust
Autism spectrum disorders, Autism, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
OXYCAC, NCT06199076: Experimental Study on Alcohol Use and Behavior in Young Adults

Terminated
2
206
Europe
Oxytocin nasal spray, Syntocinon Intranasal Spray
Karolinska Institutet
Alcohol Use Disorder
04/25
04/25
OXY-APS, NCT06881810: Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on to Psychosocial Treatment

Recruiting
2
98
Europe
Oxytocin nasal spray, Placebo
Central Institute of Mental Health, Mannheim
Schizophrenia Spectrum Disorders (SSD)
03/28
03/28
OxyPLEASURE, NCT06808516: Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy Controls

Not yet recruiting
2
42
Europe
Oxytocin nasal spray, Syntocinon, Placebo
University Hospital, Basel, Switzerland
Arginine Vasopressin Deficiency, Central Diabetes Insipidus, Oxytocin Deficiency
12/26
12/26
2012-003750-89: Empathy, Autism and Oxytocin – an investigation by means of functional magnetic resonance imaging and moleculargenetic analyses Empathie, Autismus und Oxytocin - Eine Untersuchung mittels funktioneller Bildgebung und molekulargenetischer Analysen

Ongoing
1
72
Europe
Oxytocin nasal spray (Syntocinon® spray), Syntocinon® spray, Syntocinon® spray
Philipps-University Marburg, Deutsche Forschungsgemeinschaft
high-functioning autism spectrum disorders: autistic disorder (F84.0), Asperger syndrome (F84.5), atypical autism (F 84.1) hochfunktionale Autismus-Spektrum-Störungen: Frühkindlicher Autismus (F84.0), Asperger-Syndrom (F84.5), Atypischer Autismus (F 84.1)
 
 
NCT06222749: Oxytocin and Reward Processing in Women

Recruiting
N/A
100
Europe
Intranasal oxytocin administration, Syntocinon, Intranasal placebo administration, Placebo
International Research Training Group 2804, University Hospital Tuebingen, German Research Foundation, Uppsala University
Menstrual Cycle, Hormonal Contraception
12/26
12/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
2020-001996-33: A Phase 2b/3 Study to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (COVID-19)

Not yet recruiting
3
290
Europe
Leronlimab(PRO 140), Injection, Leronlimab Injection 175mg/ml (PRO-140)
CytoDyn, Inc., CytoDyn, Inc.
Coronavirus Disease 2019 (COVID-19), Coronavirus Disease, Diseases [C] - Virus Diseases [C02]
 
 
NCT02859961: Study of PRO 140 SC As Single Agent Maintenance Therapy in Virally Suppressed Subjects with CCR5-tropic HIV-1 Infection

Completed
2/3
556
US
PRO 140 (350 mg), Leronlimab, PRO 140 (525 mg), PRO 140 (700 mg)
CytoDyn, Inc.
HIV
09/20
12/20
NCT02990858: An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 Study

Active, not recruiting
2/3
44
NA
PRO 140 SC injections
CytoDyn, Inc.
Hiv, Human Immunodeficiency Virus
06/22
08/22
NCT03902522: PRO 140 in Treatment-Experienced HIV-1 Subjects

Active, not recruiting
2/3
25
US
PRO 140, Leronlimab
CytoDyn, Inc.
HIV-1-infection
07/22
08/22
PRO 140_CD03 Extension, NCT05271370: An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study

Active, not recruiting
2/3
56
US
PRO 140 350, PRO 140 525, PRO 140 700
CytoDyn, Inc.
HIV-1-infection
12/22
04/23
NCT04347239 / 2020-001996-33: Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)

Active, not recruiting
2b
394
US
Placebos, Leronlimab (700mg)
CytoDyn, Inc., CytoDyn, Inc.
Coronavirus Disease 2019
10/21
06/22
NCT04504942: Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
2
30
US
Leronlimab
CytoDyn, Inc., Amarex Clinical Research
Solid Tumor, Adult
11/21
07/22
NCT04521114: Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis

Completed
2
87
US
Placebo, leronlimab 700 mg, PRO 140, leronlimab 350 mg
CytoDyn, Inc., Amarex Clinical Research
Nonalcoholic Steatohepatitis (NASH)
12/21
12/21
NCT02355184: An Extension of Protocol PRO 140_CD01 TS Study

Active, not recruiting
2
28
US
PRO 140 350mg weekly SQ injection., PRO 140
CytoDyn, Inc.
HIV, Human Immunodeficiency Virus
06/22
08/22
NCT05730673: Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer

Withdrawn
2
NA
700mg leronlimab weekly dose, 80mg Regorafenib at week 1, 120mg Regorafenib at week2, 160 mg Regorafenib at week 3
CytoDyn, Inc., Amarex Clinical Research
CCR5, Microsatellite Stable, Metastatic, Colorectal Cancer
05/23
08/23
NCT06699836: A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC

Recruiting
2
60
US
350 mg leronlimab, PRO 140, 700 mg leronlimab
CytoDyn, Inc., Syneos Health
Metastatic Colorectal Cancer (mCRC)
06/28
08/28
NCT03838367: Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC

Active, not recruiting
1/2
48
US
350 mg leronlimab, PRO 140, 525 mg leronlimab, 700 mg leronlimab, AUC 5 Carboplatin, Maximum Tolerated Dose (MTD) of leronlimab
CytoDyn, Inc., Amarex Clinical Research
Triple Negative Breast Neoplasms
07/22
09/22
CD02_EA, NCT02759042: An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study

No Longer Available
N/A
US
PRO 140, PRO140, CCR5 antagonist, Humanized monoclonal antibody to CCR5
CytoDyn, Inc., Amarex Clinical Research
HIV
 
 
NCT04313075: A Compassionate Use Study of Leronlimab in Breast Cancer

No Longer Available
N/A
NA
Leronlimab, (PRO 140)
CytoDyn, Inc.
Metastatic Triple-Negative Breast Carcinoma
 
 
Syntocinon Nasal Spray (oxytocin intranasal) / Vyera Pharma
2012-003072-39: Oxytocin in PTSD: Effectiveness in addition to psychotherapy Oxytocine bij PTSS: Effectiviteit als toevoeging aan psychotherapie

Ongoing
4
24
Europe
Nasal drops, solution, Syntocinon, nasal spray 40 IU/ml
Academic Medical Center, University of Amsterdam, Academic Medical Center, University of Amsterdam
Posttraumatic stress disorder Posttraumatische stress stoornis, posttraumatic stress disorder posttraumatische stress stoornis, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2013-000453-44: Oxytocin, defensiveness, and grandparenting

Ongoing
4
100
Europe
Syntocinon, RVG03716, Nasal spray, Syntocinon
There are no medical conditions or diseases under investigation, There are no medical conditions or diseases under investigation, Not possible to specify
 
 
2013-000454-22: (Grand)parenting, oxytocin, and the oxytocin receptor gene

Ongoing
4
100
Europe
Syntocinon, RVG03716, Nasal spray, Syntocinon
There are no medical conditions or diseases under investigation, not applicable, Not possible to specify
 
 
2015-003336-12: Father Trials: Hormonal Experiments on Prenatal and Postnatal Parenting

Ongoing
4
120
Europe
Syntocinon, Vasostrict, RVG03716, 42023-164-25, Nasal spray, Injection, Syntocinon, Vasostrict
Universiteit Leiden, European Research Council
There are no medical conditions or diseases under investigation, There are no medical conditions or diseases under investigation, Not possible to specify
 
 
2016-000367-16: The oxytocin effect in adolescence

Ongoing
4
256
Europe
oxytocin, oxytocin, Nasal spray, Syntocinon Nasal Spray
Radboud University Nijmegen, Radboud University Nijmegen
We examine the effect of oxytocin administration on empathy and emotion recognition in healthy adolescents and adolescents with antisocial behavior and history of severe psychological trauma, adolescents with antisocial behavior and history of trauma, Psychiatry and Psychology [F] - Behaviours [F01]
 
 
2017-000298-35: Oxytocin, friendship and dealing with emotions

Ongoing
4
180
Europe
Syntocinon, RVG 03716, Nasal spray, Syntocinon nasal spray
Tilburg University, Tilburg University, Center of Research on Psychological and Somatic disorders
There are no medical conditions or disease under investigation. Er worden geen ziekten onderzocht, not applicable niet van toepassing, Psychiatry and Psychology [F] - Psychological processes [F02]
 
 
2018-004081-34: Oxytocin and the relationship between doctor and patient. Oxytocine en de relatie tussen arts en patient

Ongoing
4
76
Europe
Oxytocin, Oxytocin, Nasal spray, Syntocinon nasal spray
Healthy individuals, Healthy individuals, Psychiatry and Psychology [F] - Psychological processes [F02]
 
 
2022-003670-22: Clinical trial to evaluate the efficacy of the combination of oxytocin plus self-compassion training in patients with Borderline Personality Disorder Estudio para evaluar la eficacia de la combinación de oxitocina más entrenamiento en autocompasión en pacientes con Trastorno Límite de Personalidad

Not yet recruiting
4
80
Europe
Nasal spray, solution, Syntocinon
Institut de Recerca Hospital de la Santa Creu i Sant Pau - IIB Sant Pau, Instituto de Salud Carlos III
Borderline personality disorder Trastorno Límite de la Personalidad, Borderline personality disorder Trastorno Límite de la Personalidad, Psychiatry and Psychology [F] - Behaviours [F01]
 
 
2013-004437-33: Effets de l'administration intranasale répétée d'ocytocine chez des patients adultes présentant un syndrome de Prader-Willi

Ongoing
3
39
Europe
Nasal spray, Syntocinon
Centre Hospitalier de Toulouse, Centre Hospitalier de Toulouse
Prader-Willi syndrom Syndrome de Prader-Willi, Prader-Willi syndrom syndrome de Prader-Willi, Diseases [C] - Hormonal diseases [C19]
 
 
2010-024202-34: group-therapy, autism and oxytocin - an investigation with the question "Does oxytocin (OT) enhance therapy effects in autism?“ Gruppentherapie, Autismus und Oxytocin - Eine Untersuchung, mit der Fragestellung: "Erhöht Oxytocin den Therapieeffekt bei Autisten?"

Ongoing
3
210
Europe
SyntocinonⓇSpray, 11.266, Nasal spray, SyntocinonⓇSpray
Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters am Zentralinstitut für Seelische Gesundheit, Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters am Zentralinstitut für Seelische Gesundheit
high-functioning autismus spectrum disorders: autistic disorder (F84.0), Asperger syndrome (F84.5), atypical autism (F84.1) Hochfunktionale Autismus-Spektrum-Störung: Frühkindlicher Autismus (F84.0), Asperger-Syndrom (F84.5), Atypischer Autismus (F84.1), autism Autismus, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2018-000769-35: The use of Oxytocin for Autism Spectrum Disorders: Investigating the effect on behavior and at the level of the brain.

Ongoing
3
60
Europe
Syntocinon (oxytocin), RVG 03716, Nasal spray, Syntocinon (oxytocin), nasal spray 40 IE/ml
University Hospital, KU Leuven, Research Council KU Leuven, Society In Science - ETH Zurich
Autism Spectrum Disorders, Autism Spectrum Disorders, Psychiatry and Psychology [F] - Psychological processes [F02]
 
 
2016-003273-18: Oxytocin intranasal administrations in children with Prader-Willi syndrome aged from 3 to 12 years.

Not yet recruiting
3
40
Europe
Nasal spray, Syntocinon
University Hospital of Toulouse, University Hospital of Toulouse
Prader-Willi Syndrom, Prader-Willi Syndrom, Diseases [C] - Hormonal diseases [C19]
 
 
2011-006302-28: Dopamine modulation of oxytocin prosocial effects Modulazione dopaminergica dell’effetto prosociale dell’ossitocina

Ongoing
2
50
Europe
Nasal spray, Syntocinon nasal Spray
UNIVERSITA' DEGLI STUDI DI PARMA, Defiante farmaceutica
HEALTHY VOLUNTEERS. FOR PATIENTS WITH AUTISM OR SCHIZOPHRENIA VOLONTARI SANI PER INDICAZIONE DESTINATA A PAZIENTI AUTISTICI O SCHIZOFRENICI, HEALTHY VOLUNTEERS. FOR PATIENTS WITH AUTISM OR SCHIZOPHRENIA VOLONTARI SANI PER INDICAZIONE DESTINATA A PAZIENTI AUTISTICI O SCHIZOFRENICI, Psychiatry and Psychology [F] - Behaviours [F01]
 
 
2012-005325-67: Evaluation of tolerance, suckling and food intake after repeated nasals administrations of Oxytocin in PWS infants Etude de tolérance d’administrations intranasales répétées d’ocytocine selon 3 schémas d’administration chez des bébés présentant un syndrome de Prader-Willi

Ongoing
2
18
Europe
Nasal spray, Syntocinon
Centre Hospitalier de Toulouse, Centre Hospitalier de Toulouse
Prader Willi Syndrom Syndrome de Prader-Willi, Prader Willi Syndrom Syndrome de Prader-Willi, Diseases [C] - Hormonal diseases [C19]
 
 
2014-005452-26: Effect of intranasal oxytocin on sosial cogitive tasks in autism spectrum disorder

Not yet recruiting
2
18
Europe
Oxytocin, Nasal spray, solution, Syntocinon
OptiNose AS, OptiNose AS
Autism spectrum disorder, Autism, Psychiatry and Psychology [F] - Psychological processes [F02]
 
 
2013-003067-59: Oxytocin Trial Protocollo Ossitocina

Ongoing
2
30
Europe
Syntocinon, N.A., Nasal spray, solution, Syntocinon
AZIENDA OSPEDALIERA G. BROTZU, Fondazione Banco di Sardegna
Autism Spectrum Disorder Disturbo dello Spettro Autistico, Is a condition charaterized by abnormalities in the domains of communication and socialization and by a restricted and repetitive pattern of interests and activities. E' una condizione clinica caratterizzata da anomalie nei settori della comunicazione e della socializzazione e da attivit¿ ridotte e ripetitive., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2014-004762-23: NO Etude de l’effet de l’ocytocine en spray nasal sur les activations cérébrales liées à l’attachement en population générale (OTACLA)

Not yet recruiting
2
80
Europe
syntocinon, Nasal spray, Syntocinon
CHRU Besançon, CHRU Besançon
sujets à l'attachement insécure sujets à l'attachement insécure, sujets à l'attachement insécure sujets à l'attachement insécure, Psychiatry and Psychology [F] - Psychological processes [F02]
 
 
2019-001910-40: Emotion recognition training combined with oxytocin in residential youth

Ongoing
2
60
Europe
oxytocin, RVG03716, Nasal spray, Syntocinon Nasal Spray
Radboud University, Radboud University
We examine whether oxytocin administration can improve the effectiveness of emotion recognition training compared to placebo in residential youth with antisocial behavior, Adolescents with antisocial behavior exhibiting aggression and delinquency, Psychiatry and Psychology [F] - Behaviours [F01]
 
 
2019-002280-10: Oxytocin nasal spray in the treatment of benzodiazepine withdrawal

Not yet recruiting
2
50
Europe
Syntocinon, Nasal spray, suspension, Syntocinon
St. Olav's University Hospital, St. Olavs University Hospital, Norwegiand University of Science and Technology, Lade Addiction Treatment Center
Benzodiazepine withdrawal and craving, Benzodiazepine withdrawal and craving, Not possible to specify
 
 
2022-000156-11: Oxytocin and the development of attachment: Looking beyond the expected? Oxytocine en de ontwikkeling van gehechtheid: een blik voorbij de verwachting?

Ongoing
2
200
Europe
Syntocinon (oxytocin), Nasal spray, Syntocinon (oxytocin), nasal spray 40 IE/ml
KU Leuven, FWO
General healthy population children (ages 8 - 13 years old). Gezonde kinderen uit de algemene populatie (tussen 8 en 13 jaar oud)., General population children (ages 8 - 13 years old). Gezonde kinderen uit de algemene populatie (tussen 8 en 13 jaar oud)., Psychiatry and Psychology [F] - Psychological processes [F02]
 
 
NCT06757517: Effects of Intranasal Oxytocin in the Treatment of Benzodiazepine Withdrawal: A Pilot RCT

Recruiting
2
60
Europe
Oxytocin nasal spray, Syntocinon, Saline (NaCl 0,9 %) (placebo)
St. Olavs Hospital, Norwegian University of Science and Technology, Lade Behandlingssenter, Blå Kors
Benzodiazepine Dependence
12/25
12/25
2022-000254-28: Interest of oxytocin as an adjuvant treatment of psycho-educational measures in challenging behaviors in children with autism spectrum disorders and moderate to severe intellectual disability: feasibility and safety study ntérêt de l’ocytocine comme traitement adjuvant des mesures psycho-éducatives dans les comportements-défis chez les enfants avec troubles du spectre de l’autisme et handicap intellectuel moyen à profond : l’étude de faisabilité et de sécurité

Not yet recruiting
2
30
Europe
Syntocinon (Oxytocin), Nasal spray, solution, Syntocinon
University Hospital of Toulouse, French Ministry of Health
autism autisme, autism autisme, Psychiatry and Psychology [F] - Behaviours [F01]
 
 
2022-000603-12: Oxytocin and postpartum depression

Not yet recruiting
2
35
Europe
oxytocin, RVG03716, Nasal spray, Syntocinon Nasal Spray
Radboud University, Radboud University
We examine the effects of oxytocin on mother-infant interaction among mothers with a postpartum depression, postpartum depression, Psychiatry and Psychology [F] - Behaviours [F01]
 
 
IN-OXT, NCT02505984: Preventing Postpartum Depression With Intranasal Oxytocin

Completed
2
56
US
Oxytocin, Syntocinon, Placebo, Salt solution
Massachusetts General Hospital, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Depression, Postpartum, Anxiety
05/23
05/23
2021-006531-26: A trial of intranasal oxytocin in youth with autism spectrum disorders evaluating social and repetitive behaviors

Not yet recruiting
2
128
Europe
Nasal spray, Syntocinon
Oslo University Hospital, Kavli Trust
Autism spectrum disorders, Autism, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
OXYCAC, NCT06199076: Experimental Study on Alcohol Use and Behavior in Young Adults

Terminated
2
206
Europe
Oxytocin nasal spray, Syntocinon Intranasal Spray
Karolinska Institutet
Alcohol Use Disorder
04/25
04/25
OXY-APS, NCT06881810: Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on to Psychosocial Treatment

Recruiting
2
98
Europe
Oxytocin nasal spray, Placebo
Central Institute of Mental Health, Mannheim
Schizophrenia Spectrum Disorders (SSD)
03/28
03/28
OxyPLEASURE, NCT06808516: Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy Controls

Not yet recruiting
2
42
Europe
Oxytocin nasal spray, Syntocinon, Placebo
University Hospital, Basel, Switzerland
Arginine Vasopressin Deficiency, Central Diabetes Insipidus, Oxytocin Deficiency
12/26
12/26
2012-003750-89: Empathy, Autism and Oxytocin – an investigation by means of functional magnetic resonance imaging and moleculargenetic analyses Empathie, Autismus und Oxytocin - Eine Untersuchung mittels funktioneller Bildgebung und molekulargenetischer Analysen

Ongoing
1
72
Europe
Oxytocin nasal spray (Syntocinon® spray), Syntocinon® spray, Syntocinon® spray
Philipps-University Marburg, Deutsche Forschungsgemeinschaft
high-functioning autism spectrum disorders: autistic disorder (F84.0), Asperger syndrome (F84.5), atypical autism (F 84.1) hochfunktionale Autismus-Spektrum-Störungen: Frühkindlicher Autismus (F84.0), Asperger-Syndrom (F84.5), Atypischer Autismus (F 84.1)
 
 
NCT06222749: Oxytocin and Reward Processing in Women

Recruiting
N/A
100
Europe
Intranasal oxytocin administration, Syntocinon, Intranasal placebo administration, Placebo
International Research Training Group 2804, University Hospital Tuebingen, German Research Foundation, Uppsala University
Menstrual Cycle, Hormonal Contraception
12/26
12/26

Download Options